New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
11:10 EDTTKPYY, FURXFuriex confirms Takeda to present additional EXAMINE trial data
Furiex Pharmaceuticals (FURX) confirmed that its partner Takeda Pharmaceuticals (TKPYY) will present sub-analyses from the global EXAMINE, EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome, cardiovascular safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session. These sub-analyses specifically relate to the effects of alogliptin on rates of CV mortality and hospitalization for heart failure, Furiex said. Findings from one sub-analysis demonstrated no effect on rates of CV mortality. There was also no increase in sudden cardiac death with alogliptin. The other sub-analysis demonstrated that in patients with Type 2 diabetes and recent ACS, the pre-specified composite CV outcome of first occurrence of all-cause mortality, nonfatal myocardial infarction and stroke, urgent revascularization due to unstable angina, and hospitalization for heart failure was similar for alogliptin compared with placebo.
News For FURX;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for FURX;TKPYY

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use